Lv4
630 积分 2023-01-17 加入
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
20天前
已完结
Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single‐centre, retrospective study
1个月前
已完结
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
1个月前
已完结
Ibrutinib-Related Uveitis: A Case Series from Two Tertiary Centres in the United Kingdom
1个月前
已完结
A case of toxic epidermal necrolysis with hand‐foot syndrome‐like rash following tirabrutinib treatment
1个月前
已完结
Ibrutinib-Related Uveitis in Non-Hodgkin Lymphoma Patients: A Case Report and Literature Review
1个月前
已完结
Safety study on adverse events of zanubrutinib based on WHO-VigiAccess and FAERS databases
1个月前
已完结
Successful treatment of relapsed idiopathic multicentric Castleman disease–idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report
1个月前
已完结
Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma: A multicenter, real‐world study in China
1个月前
已完结
A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia
1个月前
已完结
皖公网安备34019202002308
